Please login to the form below

Not currently logged in
Email:
Password:

DDP-4

This page shows the latest DDP-4 news and features for those working in and with pharma, biotech and healthcare.

Type 2 diabetes market set to hit $39bn by 2021

Type 2 diabetes market set to hit $39bn by 2021

In particular its new report points to three classes of drugs: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium– glucose cotransporter 2 inhibitors. ... DPP-4 inhibitors are already a widely-used

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics